{
    "nctId": "NCT00191451",
    "briefTitle": "A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Gemzar Plus Paraplatin (Plus Herceptin in HER2+ Patients) in Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Overall Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Diagnosis of metastatic breast cancer\n2. Able to visit the doctor's office at least every 14 days during the actual treatment\n3. Able to care for yourself, even if you cannot work or participate in other normal activities\n4. Your blood results must be adequate for therapy.\n5. If you are a female of childbearing potential and test negative for pregnancy, use a reliable method of birth control during and for three months following the last dose of study drug.\n\nExclusion Criteria:\n\n1. Have received gemcitabine, paraplatin, or trastuzumab for your cancer.\n2. Be pregnant or breastfeeding\n3. Have cancer to the brain and has not been treated\n4. Have another active cancer besides breast cancer\n5. Have received stem cell or bone marrow transplant for hematologic (blood type) cancer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}